Steroid induced hyperglycemia is a condition in which corticosteroid medications cause elevated blood glucose levels, often mimicking or triggering type 2 diabetes in susceptible individuals. It results from increased gluconeogenesis, insulin resistance, and reduced insulin secretion, typically emerging within days to weeks of initiating therapy.
This phenomenon occurs because synthetic glucocorticoids-such as prednisone, dexamethasone, and methylprednisolone-mimic natural cortisol. They activate pathways in the liver and muscle that increase glucose production while simultaneously reducing glucose uptake in peripheral tissues. The effect is dose-dependent and reversible upon discontinuation, though prolonged exposure may lead to lasting metabolic changes.
According to the American Diabetes Association, up to 30% of patients receiving systemic corticosteroids develop transient hyperglycemia during treatment. A 2021 study in Diabetes Care found that patients on daily doses exceeding 10 mg prednisone equivalent had a 4.3-fold higher risk of developing hyperglycemia compared to those on lower doses.
Corticosteroids disrupt normal glucose regulation through multiple mechanisms. They stimulate hepatic gluconeogenesis-the creation of new glucose from non-carbohydrate sources-by increasing expression of enzymes like PEPCK and glucose-6-phosphatase. This leads to excessive glucose release into the bloodstream even during fasting states.
At the same time, steroids reduce insulin sensitivity in skeletal muscle and adipose tissue. Insulin normally signals cells to absorb glucose from the blood. When cells resist this signal, glucose remains elevated. A 2019 study in Endocrine Reviews showed that glucocorticoids suppress insulin receptor substrate-1 (IRS-1) phosphorylation, impairing downstream signaling.
Corticosteroids inhibit insulin secretion from pancreatic beta cells. This dual action-increasing glucose output while decreasing glucose disposal-creates a net rise in blood sugar. The effect is most pronounced in individuals with pre-existing insulin resistance, such as those with obesity, polycystic ovary syndrome, or a family history of diabetes.
Steroid induced hyperglycemia primarily affects adults on long-term or high-dose corticosteroid regimens. Common indications include autoimmune diseases (rheumatoid arthritis, lupus), organ transplantation, severe asthma, and certain cancers. Patients receiving intravenous or oral corticosteroids for more than 5 days are at highest risk.
The onset is typically within 3-7 days of starting therapy. Blood glucose levels may peak around day 10 and normalize within 1-2 weeks after stopping treatment. However, in some cases, persistent hyperglycemia continues beyond drug cessation, suggesting latent diabetes was unmasked.
A clinical example: A 58-year-old woman with relapsing multiple sclerosis began oral prednisone 40 mg daily. On day 5, her fasting blood glucose rose from 92 mg/dL to 187 mg/dL. She reported increased thirst and fatigue. After tapering off steroids over 10 days, her glucose returned to baseline. This reflects the typical course of steroid-induced hyperglycemia.
There are two primary patterns of steroid induced hyperglycemia:
| Type | Description | Risk Profile |
|---|---|---|
| Transient | Blood sugar rises during treatment, returns to normal after discontinuation. | Most common; seen in ~70% of cases; resolves within 2 weeks post-taper. |
| Persistent | Glucose remains elevated after stopping steroids; indicates underlying diabetes. | Occurs in ~15-20% of patients; requires ongoing monitoring and management. |
Key risk factors include age over 50, BMI >25 kg/m², prior history of gestational diabetes, and genetic predisposition. Patients with type 2 diabetes on corticosteroids face a 2.5-fold increased risk of hospitalization due to hyperglycemic crises, according to a 2020 analysis in Journal of Clinical Endocrinology & Metabolism.
Many assume steroid induced hyperglycemia is rare or only affects people with pre-existing diabetes. In reality, it can occur in otherwise healthy individuals. A 2022 study in Metabolism found that 12% of patients without known diabetes developed fasting hyperglycemia (>126 mg/dL) during a 14-day prednisone course.
Another misconception is that all patients on steroids require insulin. Most do not. Mild elevations (140-180 mg/dL) can be managed with diet, exercise, and close monitoring. Only about 5% of patients need pharmacologic intervention during treatment.
Some clinicians confuse steroid induced hyperglycemia with diabetic ketoacidosis (DKA). DKA involves ketones, acidosis, and profound dehydration-features absent in pure steroid-induced cases. Steroid users may have high glucose but normal pH and negative urine ketones unless they are also dehydrated or stressed.
Screening for steroid induced hyperglycemia begins with fasting glucose or HbA1c before starting therapy. For patients on chronic or high-dose steroids, regular glucose checks-preferably twice daily-are recommended. Continuous glucose monitors (CGMs) offer real-time tracking and are increasingly used in outpatient settings.
Management follows a tiered approach. First-line strategies include dietary modification (low glycemic index foods), physical activity, and stress reduction. If glucose exceeds 180 mg/dL on two consecutive readings, metformin may be initiated. Insulin is reserved for values above 250 mg/dL or symptomatic hyperglycemia.
I observed this in practice during a neurology clinic visit: a 62-year-old man with giant cell arteritis started on 60 mg prednisone daily. His home glucose logs showed spikes to 220 mg/dL post-breakfast. After switching to a low-carb meal plan and adding metformin 500 mg twice daily, his average glucose dropped to 130 mg/dL within 10 days.
Patients should contact their provider if they experience frequent urination, excessive thirst, blurred vision, or unexplained fatigue. These symptoms indicate significant hyperglycemia requiring evaluation. Emergency care is needed if confusion, rapid breathing, or fruity breath develop-signs of impending DKA.
Discontinuing steroids abruptly is dangerous. Tapering under medical supervision prevents adrenal insufficiency. If hyperglycemia persists after tapering, referral to endocrinology is warranted for further workup.
Steroid induced hyperglycemia is a predictable, manageable consequence of glucocorticoid therapy. Recognizing early signs, adjusting lifestyle, and using targeted monitoring can prevent complications. Awareness and timely intervention are key to safe treatment.